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Abstract
Background and aims. Atrophic gastritis (AG) results most often from Helicobacter pylori (H. pylori) infection. AG is the
most important single risk condition for gastric cancer that often leads to an acid-free or hypochlorhydric stomach. In the
present paper, we suggest a rationale for noninvasive screening of AG with stomach-speciﬁcb i o m a r k e r s .Methods. The
paper summarizes a set of data on application of the biomarkers and describes how the test results could be interpreted
in practice. Results. In AG of the gastric corpus and fundus, the plasma levels of pepsinogen I and/or the pepsinogen
I/pepsinogen II ratio are always low. The fasting level of gastrin-17 is high in AG limited to the corpus and fundus, but low or
non-elevated if the AG occurs in both antrum and corpus. A low fasting level of G-17 is a sign of antral AG or indicates high
intragastric acidity. Differentiation between antral AG and high intragastric acidity can be done by assaying the plasma
G-17 before and after protein stimulation, or before and after administration of the proton pump inhibitors (PPI). Amidated
G-17 will rise if the antral mucosa is normal in structure. H. pylori antibodies are a reliable indicator of helicobacter
infection, even in patients with AG and hypochlorhydria. Conclusions. Stomach-speciﬁc biomarkers provide information
about the stomach health and about the function of stomach mucosa and are a noninvasive tool for diagnosis and screening
of AG and acid-free stomach.
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An expert group appointed by IARC (International
Agency for Research on Cancer) concluded in
1994 that the Helicobacter pylori (H. pylori) infection
is a group I carcinogen to humans [1]. However, the
mechanism by which the H. pylori infection causes
noncardia (distal) gastric cancer has remained
obscure. H. pylori infection induces chronic active
gastritis that develops with time in a proportion of
infected people to atrophic gastritis (AG) and acid-
free or hypochlorhydric stomach [2,3]. In AG, focal
neoplastic (dysplastic) lesions may appear that grad-
ually progress into an invasive malignancy. On aver-
age, this so-called Correa cascade concerns
approximately one-half of the gastric cancer cases
[4]. Early treatment of the infection is considered
an action of choice, as it may slow or intercept the
Correa cascade [5,6].
AG of the stomach mucosa is the highest known
independent risk factor (risk condition) for distal,
noncardia gastric cancer [4,7,8,9,10]. By deﬁni-
tion, atrophy means a loss of normal antral and/
or oxyntic glands. This loss is accompanied by
ﬁbrosis of the lamina propria and by the appearance
of new metaplastic glands of intestinal and/or pseu-
dopyloric type in the injured mucosa. AG pro-
gresses slowly and may ﬁnally result in severe,
advanced atrophy, i.e., in total or nearly total
loss of normal mucosal glands [3,11,12]. Curable
precancerous lesions and early cancers are fre-
quently found in stomachs with severe AG and
intestinal metaplasia. In an endoscopic study
from Finland, a deﬁnite neoplastic lesion was
found in 63 (4.7%) of 1344 men (age 50–69 years)
with a low plasma level of pepsinogen I (PGI), and
with moderate or severe corpus AG in the endo-
scopic histology. Of these 63 lesions, invasive can-
cer was found in 11 cases (in 7 patients the cancer
was in an “early” stage, i.e., invasion limited to the
submucosa). High-grade intraepithelial neoplasia
(dysplasia) was found in 7 men, low-grade intrae-
pithelial neoplasia in 42 men, and an ECL cell type
carcinoid tumor in 3 men [10].
Cancers appear in patients with nonatrophic H.
pylori gastritis as well, but are more infrequent than
that in AG [6,13]. Eradication of H. pylori early
enough is considered the key to preventing distal
stomach cancer, provided that the presence of neo-
plastic or preneoplastic lesions, AG, or intestinal
metaplasia is excluded before the treatment
[13,14]. It has recently been estimated in China
that one treatment of H. pylori might prevent
one distal gastric cancer in every four to six cases
undergoing the H. pylori eradication [15].
On average, half of the case with H. pylori infection
will develop AG of some degree during their lifetime,
and in around 10% of the infected subjects, the AG
will ﬁnally be moderate or severe [3,16,17]. In the
latter category, 2.5–5% may get a cancer [10].
In H. pylori infection, gastritis (chronic mononu-
clear inﬂammation) and atrophy (loss of normal
mucosal glands) tend to appear ﬁrst in the antrum
and angulus and will tend to progress by pylorocardial
extension [11]. The “atrophic border,” which can
even be seen in ordinary endoscopy, moves upward
with time, ﬁnally resulting in AG that occupies the
whole stomach [11].
Nonatrophic H. pylori gastritis raises the risk of
gastric cancer fourfold on average, and the risk may
rise to 15-fold in patients with AG [13]. In subjects
with severe panatrophy (AG in both antrum and
corpus, i.e., severe multifocal atrophic gastritis), irre-
spective of the presence or absence of ongoing
H. pylori infection, the cancer risk may even be up
to 90-fold compared with the risk in subjects with a
healthy stomach mucosa [8].
Eradication of H. pylori will inevitably improve
stomach health in subjects with nonatrophic H. pylori
gastritis, or even with mild gastric atrophy as indi-
cated, for example, by an increase in the serum levels
of PGs after a successful H. pylori therapy [18]. Severe
precancerous conditions or lesions, like AG, intestinal
metaplasia or dysplasia, may not always regress and
may even progress to invasive cancer despite a suc-
cessful H. pylori eradication [13]. This can even occur
at intervals longer than a decade [14,19].
The plasma biomarker test can be used for the
screening of patients with a “sick stomach mucosa”
and for those with AG in particular, i.e., patients
eligible for gastroscopy and endoscopic surveillance
for cancer risk [20,21]. The biomarker screening
would help, in addition, in the identiﬁcation of the
patients with a “healthy” stomach mucosa, in whom
the cancer risk is low, and in whom the endoscopy
may not be the ﬁrst important diagnostic procedure.
In a recent survey with a biomarker panel among
4256 Finnish adult volunteers (mean age of 56 years;
range 18–92 years), the overall prevalence of H. pylori
infection was 19% in the whole population studied,
and the prevalence of moderate or severe (advanced)
atrophic corpus gastritis was 6% (110 persons) among
people aged 60 or more [22]. Since the cancer risk in
advanced AG is around 5%, one may estimate that at
least 6 people out of the 4256 persons screened would
be liable to develop stomach cancer. It is especially
noteworthy that the stomach mucosa could be clas-
siﬁed as normal and healthy (no H. pylori gastritis, no
AG) by the biomarkers in 77% of all 4256 subjects
analyzed [22].
Atrophic gastritis and biomarkers 137Cancer risk is not the only medical challenge asso-
ciated with an achlorhydric stomach and AG. AG and
acid-free stomach may also lead to other diseases than
the gastric illnesses alone. Such “extra-gastric” dis-
eases are, for example, malabsorptions of vitamin B12
and malabsorption of certain micronutrients and
pharmaceuticals, or an increased risk of gastrointes-
tinal (GI) and pulmonary infections, especially among
the elderly [23,24]. From viewpoints of the public
health, these non-neoplastic and extra-gastric conse-
quences of AG and acid-free stomach may even be
more important than the cancer burden.
Objectives of the paper
The present paper is a summary of a set of studies
published on the application of stomach-speciﬁc bio-
markers in noninvasive diagnosis of AG. We focus on
reviewing the applicability, background, and rationale
of the PGI and PGII, gastrin-17, and H. pylori anti-
bodies in assessment of the stomach health, and in
screening of the AG and acid-free stomach. Several
excellent reviews on the use of PGs alone have been
published earlier [25,26,27,28]. The present paper
focuses on the application of a more comprehensive
set of tests in which also the plasma levels of PGII,
amidated gastrin-17, and H. pylori antibodies are
noted and assayed, in addition to the PGI alone.
We argue why the screening and diagnosis of AG
with biomarkers are noteworthy in clinical practice,
and we suggest how the interpretation of the bio-
marker tests could be carried out.
The effects of AG on gastric physiology and
plasma biomarkers
In AG, the normal functional cells and glands in the
gastric mucosa decrease in number and ﬁnally totally
disappear. In corpus AG, the acid-producing parietal
cells and the PG-secreting chief cells will disappear and,
concomitantly, the secretion of stomach acid, PGs
(pepsins), and intrinsic factor will decrease. The stom-
ach becomes hypochlorhydric and ﬁnally achlorhydric
(acid free). The decrease in acid output and the
decrease in the plasma levels of PGI and the PGI/II
ratio correlate well with the grade and extent of the
corpus AG, as validated by thebiopsy histology or by the
pentagastrin test [29,30]. There is some evidence that
the PGI/II ratio is a more reliable biomarker for the
corpus AG than the PGI test alone, particularly in
studies from Asia [20,25]. Atrophy of antral (pyloric)
glands results in loss of antral G cells, and, subse-
quently, in decreased capacity of the antrum to synthe-
size and secrete amidated gastrin-17 into the circulation.
Parallel assays of PGI, of the PGI/II ratio, and of
amidated gastrin-17 comprise an exact and validated
set or panel of biomarkers that reﬂect the degree of
mucosal inﬂammation, the extent and grade of AG in
the stomach, and the capacity of the existing mucosa
to secrete acid and gastrin-17 [29,31,32]. Thus, the
changes in plasma levels of the biomarkers reﬂect
changes in the structure and function of the gastric
mucosa, i.e., the abnormal levels are signs of a “sick”
stomach mucosa and indicate failures in the feedback
mechanism that controls the acid output in the stom-
ach (Figures 1 and 2). Reciprocally, normal plasma
levels of these biomarkers indicate that the stomach
mucosa is healthy with normal structure and function.
In atrophy of the antral mucosa, and with a
concomitant disappearance of the gastrin-synthesiz-
ing and secreting G cells, the plasma level of gastrin-
17 is low not only in fasting conditions but also in
stimulated conditions, i.e., after a protein intake,
bombesin (gastrin-releasing peptide) stimulation, or
after PPI administration [30,31,32,33]. Conversely,
in subjects with a normal number of antral G cells, the
plasma level of gastrin-17 will increase markedly after
the stimulation. The fasting levels of amidated
gastrin-17 tend to be low (<1–2 pmol/l) in subjects
at risk for erosive esophagitis and Barrett’s esophagus,
in cases where the patient suffers from gastroesoph-
ageal reﬂux [34].
Recently, an international group of gastroenterol-
ogists and pathologists developed a staging system
(OLGA staging) for reporting AG in endoscopic
biopsies from antrum and corpus [35,36]. The
OLGA system (Operative Link for Gastritis Assess-
ment) categorizes patients into ﬁve stages (0–IV)
according to the grade and extension of histologically
assessed AG in the stomach. In a multicenter follow-
up study on OLGA, stages III and IV were signiﬁ-
cantly associated with an increased gastric cancer risk
[34]. At the same time, the staging correlated well
with the plasma levels of the stomach biomarkers. The
ratio of PGI/PGII decreased with increasing OLGA
stage (from 0 to IV).
Impaired absorption of vitamin B12,
micronutrients, and pharmaceuticals in acid-
free stomachs
As AG progresses in the gastric corpus and fundus,
the secretion of intrinsic factor from oxyntic glands
decreases and will ﬁnally cease completely. Hypo-
chlorhydria impairs the release of the protein-
bound dietary vitamin B12, and the lack of intrinsic
factor prevents the adequate absorption of the dietary
vitamin B12 in the small intestine. All subjects with
moderate or severe corpus atrophy are at risk for this
138 L. Agréus et al.malabsorption, and thus at risk for neurological and
metabolic consequences known to be related to the
vitamin B12 deﬁciency [23,37,38].
In a Finnish population-based study, every second
patient with moderate or severe corpus AG had, at the
time of the diagnosis, a low (170–220 pmol/l) or very
low (below 170 pmol/l) serum vitamin B12 level, often
with a simultaneous increase in the serum homocys-
teine (over 15 micromol/l) [23]. At present, by extrap-
olation, up to 8% (15,000) of Finns over the age of
60 belong to this risk category for vitamin B12 mal-
absorption. In Russia there would then be about
500,000 people having severe corpus AG and vitamin
B12 malabsorption, most of these without proper
diagnosis or substitution therapy. In Spain, Germany,
and Italy, the corresponding numbers would range
from 100,000 to 200,000. In the USA, it has been
estimated earlier that approximately 800,000 elderly
people have undiagnosed and untreated pernicious
anemia due to vitamin B12 deﬁciency [35].
With a diminished gastric acid secretion, the absorp-
tion of certain divalent micronutrients such as iron,
calcium, magnesium, and zinc may be impaired
[24,39,40,41,42]. The release and conversion of the
micronutrientsintoactively absorbableionsrequirethe
presence of stomach acid [24]. One may assume that
in a signiﬁcant proportion of elderly people, cognitive
disturbances, neurodegenerative and vascular
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Figure 1. Algorithmon how nonatrophic Helicobacter pylorigastritis andatrophic gastritisin differentpartsof the stomacharelinked with risk of
gastric cancer, peptic ulcer disease, and with failures in absorption of dietary vitamin B12 and some essential micronutrients. Abbreviations:
N = stomach mucosa is healthy, no risks of gastric diseases; DU = duodenal ulcer; GU = stomach ulcer; B12, Ca, Fe = malabsorption of dietary
vitamin B12 (neurological disease), iron (anemia), and calcium.
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Figure 2. Algorithm on how the plasma levels of stomach biomarkers are linked with nonatrophic Helicobacter pylori gastritis (previously
so-called superﬁcial gastritis) and with atrophic gastritis of various topographic phenotypes. Abbreviations: N = stomach mucosa is healthy;
Hp = H. pylori; PGI = plasma pepsinogen I (pepsinogens I/II); G-17 = plasma gastrin-17 amidated.
Atrophic gastritis and biomarkers 139disorders, encephalopathies, anemias, and osteoporo-
sismaybecausedbyundiagnosedmalabsorptionofthe
essential micronutrients and vitamin B12 due to a
hypochlorhydric or acid-free stomach, and AG [42].
The inﬂuence of achlorhydria on absorption of
perorally administered pharmaceuticals is poorly
known. However, many pharmaceuticals need the
presence of stomach acid for proper absorption.
For example, the absorption of calcium carbonate,
dipyridamole, some iron formulations, and antifungal
medicines, such as ﬂuconazole and itraconazole, thy-
roxin, and atazanavir, are known to be impaired in
acid-free subjects [43,44,45,46].
Risk of GI and pulmonary infections when the
stomach is acid free
Stomach acid is a natural defense against oral
microbes [47]. An acid-free stomach is not defended,
independently of whether the achlorhydria is caused
by AG or acid inhibitors (PPI). The risks of pneu-
monia and intestinal infections (e.g., giardiasis,
malaria, Clostridium difﬁcile, etc.) have been reported
to be increased in hypochlorhydric subjects
[47,48,49,50].
Appearance of carcinogens in an
acid-free stomach
An atrophic and achlorhydric stomach is always col-
onized to a massive extent with bacteria and fungi
representing the normal oral ﬂora [51,52,53]. This
colonization leads to reduction of nitrates to nitrites,
and to formation of potential carcinogenic N-nitroso
compounds and acetaldehyde in the stomach
[4,54,55].
Acetaldehyde is an abundant novel carcinogenic
compound in the upper GI tract, in the stomach in
particular. In 2009, IARC concluded that the acetal-
dehyde derived from alcoholic beverages, and formed
from ethanol endogenously, is a group 1 carcinogen in
humans. This conclusion was based on uniform epi-
demiological, genetic, biochemical, and microbiolog-
ical evidence from studies with alcohol-consuming
individuals carrying, for example, the alcohol dehy-
drogenase (ADH) and aldehyde dehydrogenase
(ALDH2) gene mutations. In the presence of ethanol,
these mutations lead to an increased exposure of the
upper digestive tract mucosa to acetaldehyde
[52,53,56], resulting in an increased cancer risk
[57,58,59,60,61,62,63,64].
Tobacco smoking, which is a signiﬁcant source of
acetaldehyde in the upper GI tract, is a known inde-
pendent risk factor for stomach cancer
[65,66,67,68,69,70]. In a prospective Japanese
follow-up study, the risk of stomach cancer was, in
comparison with the H. pylori-negative nonsmokers,
11-fold among the H. pylori-positive smokers, 6-fold
among H. pylori-negative smokers, and 7-fold among
H. pylori-positive nonsmokers [69]. As a water-
soluble agent, acetaldehyde readily dissolves in saliva
and gastric juice in mutagenic concentrations [65].
The esophagus may, in addition, be exposed to acet-
aldehyde from gastric juice via gastroesophageal
reﬂux. Novel L-cysteine-releasing compounds that
are able to bind and inactivate carcinogenic acetalde-
hyde locally in the stomach may provide a new ther-
apeutic tool to eliminate the acetaldehyde from the
stomach [71].
Why is the diagnosis of AG important in cancer
prevention?
Early endoscopic diagnosis of gastric cancer or pre-
cancerous lesions (intragastric neoplasia, dysplasia)
followed by proper endoscopic or surgical therapy is
the best available guarantee to improve the stomach
cancer prognosis. The noninvasive diagnosis of pre-
cancerous conditions (H. pylori gastritis or AG) pro-
vides a tool for identiﬁcation of the subjects at cancer
risk, i.e., identiﬁcation of the subjects in whom a
diagnostic endoscopy and cancer surveillance are
necessary irrespective of the presence or absence of
symptoms.
About one million new cases of stomach cancer
appeared in 2008 (988,000 cases, 7.8% of all cancers)
worldwide, making the gastric cancer currently the
fourth most common malignancy in the world [72].
Because of dismal prognosis, stomach cancer is the
second leading cause of cancer deaths in both sexes
worldwide (736,000 deaths, 9.7% of total). The high-
est mortality rates are in Eastern Asia (28.1 per
100,000 in men and 13.0 per 100,000 in women)
and the lowest in Northern America (2.8 and
1.5 respectively).
Cancer risk groups
The risk of stomach cancer is insigniﬁcant, nil in
practice, in people with a normal, healthy gastric
mucosa (no H. pylori infection or AG). Exceptions
are the rare cases associated with inherited gene errors
or speciﬁc cancer syndromes [73,74,75,76]. In cases
with inherited gene errors, the cancer is usually seen
in successive generations, appears often before age 60,
and is often of a diffuse subtype [75]. In most coun-
tries, even in those with relatively low H. pylori prev-
alence, less than 10% of the gastric cancer patients
have a normal gastric mucosa (see Table I).
140 L. Agréus et al.Autoimmunity is one of the etiopathogenetic
mechanisms of corpus AG, and patients with auto-
immune diseases are, therefore, a special risk group
for stomach cancer. On the other hand, AG may be
rarely linked to autoimmunity alone. Studies from
Italy and Finland indicate that the H. pylori infection
is the most important cause of AG in Europe, also in
the cases in which the AG is limited to the gastric
corpus, and in which the phenotype of AG resembles
that of the autoimmune disease [77,78,79]. In these
studies, signs of an active or a past H. pylori infection
could be found in 70–80% of the people with
advanced corpus AG [79].
The importance of H. pylori infection in stomach
cancer pathogenesis has also been challenged.
According to the so-called Indian/African enigma,
gastric cancer incidence is low in some parts of
Asia and Africa in spite of a high H. pylori infection
rate [80,81]. So far, this enigma has remained
unexplained.
Gene polymorphisms affecting acetaldehyde metabolism
Functional gene polymorphism resulting in a deﬁ-
cient ability to detoxify carcinogenic acetaldehyde
characterizes some speciﬁc groups of people at risk
for gastric cancer. A relative risk of 3.5 for stomach
cancer has been reported among ALDH2-deﬁcient
Japanese heavy drinkers [82,83]. In a more recent
Japanese study including 45 alcoholics with gastric
cancer and 281 controls, the odds ratio (OR) for those
with severe corpus AG in combination with
ALDH2 deﬁciency was 39 as compared with an
OR of 18 for those with AG alone and OR of
10 for those with the ALDH2 deﬁciency alone [60].
The Asian-type ALDH2 mutation is almost non-
existent in Europe. However, in a European multi-
center case-control study including 811 cases and
1083 controls, an ALDH2 variant with a deﬁcient
ability to detoxify acetaldehyde was found to be asso-
ciated with a 1.8-fold risk of upper aerodigestive tract
cancers among moderate drinkers [84]. The OR was
6 among heavy drinkers. In a study from Poland, the
same ALDH2 variant was found to be associated with
a 2.3-fold risk of stomach cancer among daily drinkers
and 3-fold risk was reported among those with 40 or
more drink-years [85].
Age and sex
The incidence of gastric cancer increases exponen-
tially with age. In multivariate analyses, age is, how-
ever, not an independent risk factor for gastric
cancer – it is only a surrogate marker [8]. The cancer
risk is a result of the prevalence of H. pylori gastritis
and AG in the cohort of people under examination,
not of the age of the people in the cohort. In practice,
the gastric cancer risk in a 70-year-old subject with a
normal and healthy stomach mucosa (no H. pylori
gastritis or AG) is as low as the cancer risk in a
30-year-old person with a healthy stomach (see
Table I).
Worldwide, the age-speciﬁc incidence of gastric
cancer of intestinal type is approximately twice as
high in males as in females. There is evidence suggest-
ing that this difference is caused by estrogens that
protect the females from stomach cancer instead of
being a result of any differences in gastritis or AG
between the sexes [86].
Biomarker tests in assessing the stomach
health
Patients with alarming symptoms (bleeding, black
stools, weight loss, sudden stomach pains, obstruc-
tion, etc.) are to be referred to gastroscopy and to
consultation by a gastroenterologist without any prior
testing, and even without any prior H. pylori tests. In
other instances, the estimation of stomach health and
the assessment of a need of prompt diagnostic
endoscopy can be done easily with the biomarker
examination (Figures 1,2,3).
Table I. Age-group speciﬁc prevalences of Helicobacter pylori nonatrophic (superﬁcial) and atrophic gastritis in patients with advanced
(invasive) gastric cancer. The series was collected in Finland in 1980–2000 from consecutive patients referred to endoscopy and/or surgery in a
Helsinki university hospital, Jorvi Hospital, Espoo. “Healthy” stomach mucosa means that the patient has no gastritis, no Helicobacter infection,
nor metaplastic or atrophic changes (AG) in antrum or corpus mucosa in the available surgical and/or endoscopic tissue specimens.
“Healthy stomach” mucosa Nonatrophic gastritis Atrophic gastritis
Age group, years Number of patients No. (%) No. (%) No. (%)
<50 34 5 (15%) 28 (82%) 1 (3%)
50–59 33 3 (9%) 15 (45%) 15 (45%)
60–69 57 6 (11%) 19 (33%) 32 (56%)
70–79 60 1 (2%) 10 (17%) 49 (82%)
80- 22 1 (5%) 2 (9%) 19 (86%)
Total 206 16 (8%) 74 (36%) 116 (56%)
Atrophic gastritis and biomarkers 141As simple guidelines, the biomarker examinations
can be described as follows [83]:
A. No H. pylori infection, no AG. Stomach mucosa is
normal and healthy. All biomarker tests are normal:
Gastroscopy is unlikely to reveal any relevant
pathology in the stomach, except on some speciﬁc
grounds, such as prolonged NSAID use. The nor-
mal test results indicate that the stomach mucosa
operates normally and the mucosa has normal
structure. The risk of gastric cancer or peptic ulcer
disease is very small, provided that a patient does
not use anti-inﬂammatory drugs, does not smoke,
and has no family history of gastric cancer.
B. H. pylori infection without AG (chronic non-AG);
only H. pylori antibody test is positive, and other
biomarker test results are normal. In these cases,
the need of gastroscopy is to be decided by the
physician and based on the patient’s wishes. The
risk of gastric cancer is small but not nil. Partic-
ularly, diffuse-type gastric cancer can occur in non-
AG. All non-neoplastic disease conditions (peptic
ulcer disease) heal, and the risk of the stomach
diseases decreases if the H. pylori infection is
eradicated.
C. AG (plasma levels of the biomarkers indicate
AG, independently of whether the H. pylori test is
positive or negative): Stomach is acid free (hypo-
chlorhydric/achlorhydric) if AG is in the corpus
and is moderate or severe. Cancer risk is notewor-
thy but the risk of peptic ulcer is nil. Consultation
by a gastroenterologist is necessary and a gastros-
copy needs to be performed due to increased
cancer risk. In patients with a positive H. pylori
result, eradication of the bacterium should be
carried out. In cases with acid-free stomach (severe
corpus atrophy), the use of PPIs or other medica-
tions for acid inhibition are irrelevant. In subjects
with gastroesophageal reﬂux, the reﬂuxate is not
acid if the AG occurs in the corpus and is moderate
or severe.
In developed countries, about two-thirds of the
adult patients who visit the physician because of
unexplained stomach problems (dyspepsia) belong
to group A, and 2.5–5% belong to group C [83].
In Asian and developing populations, some 20–30%
of patients may belong to group A and 20% to
group C, on average.
Diagnosis of H. pylori infection
The diagnostic accuracies of both UBT (Urea Breath
Test) and stool antigen tests depend on the number of
bacteria (H. pylori) in the stomach mucosa (coloni-
zation). These tests give false-negative results in up to
one-half of the patients with AG and acid-
free stomach [87]. Moreover, the UBT and stool
antigen tests often give false-negative H. pylori
results in conditions such as bleeding peptic
ulcer disease or if the patient is receiving antibiotics
or PPIs [88,89].
Serological antibody tests are independent of all the
above-mentioned shortcomings, providing that the
technical quality and diagnostic validity of the anti-
bodies applied are tested [90,91,92,93,94]. The H.
pylori tests alone, neither the serological ones, do not
give any information of the presence or absence of
AG. These tests provide information only of the
presence or absence of an ongoing H. pylori infection,
nothing else.
The Maastricht III Consensus Report accepts val-
idated serological tests as ﬁrst-line options in the
testing of H. pylori infection [95].
The “test-and-treat” strategy proposed by the
Maastricht Consensus meetings for treatment of dys-
pepsia in patients under the age of 45 years recom-
mend testing for H. pylori alone. This strategy has
been criticized in several studies, in particular,
from Asia [96,97,98,99]. In these investigations, the
H. pylori assay alone is not considered reliable enough
to exclude the cancer risk in populations in which the
stomach cancer (and H. pylori gastritis or AG) is
frequent also among subjects below the age of 45.
Diagnosis of AG
Gastroscopy with biopsy microscopy provides an
invasive but reliable method (gold standard) for the
diagnosis of AG. The biomarker test panel (PGI and
PGII, and amidated gastrin-17) is an alternative non-
invasive tool to diagnose and screen AG, even at basic
health-care centers without endoscopic facilities
[29,30,31,32,100,101,102].
Diagnosis of gastritis and AG with the biomarkers
The sensitivity and speciﬁcity of the biomarker test
panel in AG were 71–83% and 95–98%, respectively,
when a commercial test panel (GastroPanel
 ,H e l -
sinki, Finland) was validated against the ﬁndings in
endoscopic biopsy histology in consecutive series of
404 outpatients with dyspepsia and in a population-
based sample of approximately 1000 North Euro-
pean subjects undergoing gastroscopy [12,103].
Correspondingly, the sensitivity and speciﬁcity of
the biomarker test panel to diagnose normal and
“healthy” (no H. pylori gastritis, no AG) stomach
mucosa in the population-based sample of the
1000 subjects were 89% (95% CI 86–92%) and
92% (90–95%), respectively [12].
142 L. Agréus et al.The PGI test and the ratio of PGI and PGII have
been used in the diagnostics of atrophic corpus gas-
tritis worldwide for decades [28,32,104,105,106,107,
108,109,110,111,112,113,114,115,116,117].
The knowledge of the plasma level of amidated
gastrin-17 together with the PG also enables identi-
ﬁcation of patients with antral AG and those with
extremely extensive AG, i.e., patients with atrophic
pangastritis (AG multifocally in the whole stomach).
In a case-control study from Japan, the highest cancer
risk (risk ratio 25) was observed in patients with low
plasma levels of PGI (or ratio PGI/PGII) and with a
concomitantly low amidated gastrin-17. All these
patients exhibited multifocal AG (AG in both antrum
and corpus) in endoscopy and biopsy histology [102].
In H. pylori infection, the plasma levels of PGII tend
to increase and are often high (>10 mg/l) in the
presence of active Helicobacter gastritis. Increased
plasma levels of PGII are an accessory indicator of
an ongoing H. pylori infection and are an indirect sign
of the “activity” of the H. pylori infection [115]. In
addition, the plasma levels of PGII may increase in
any major gastric irritation, like the NSAID damage,
of the stomach mucosa [115].
In assessment of gastric cancer risk by biomarkers
in a 10-year follow-up of 5209 asymptomatic middle-
aged Japanese, the high plasma levels of H. pylori
antibodies and the low plasma levels of PGI and/or
the ratio of PGI to PGII predicted the cancer risk
signiﬁcantly [116]. The risk ratio reached the level
3.5 (95% CI: 2.0–6.4) when a low PGI (30 mg/l or
lower) was used as a criterion and 3.0 (2.5–7.3) when
a low ratio (3 or lower) of PGI/PGII ratio was used as
a cutoff.
Value of gastrin-17 as a biomarker of stomach
physiology
The plasma levels of amidated G-17 vary extremely
rapidly reﬂecting the normal physiology of the gas-
trin–acid feedback mechanism in the diurnal control
of the acid secretion. The plasma levels of amidated
G-17 are sensitive to all physiological stimuli, drugs,
and diet. Prolonged use of PPIs raises the plasma
Healthy stomach H. pylori gastritis
H. pylori -
PGI, PGII, PGI/PGII,
G-17b
normal
H. pylori +
PGI, PGII, PGI/PGII,
G-17b
normal
H. pylori + H. pylori - H. pylori + H. pylori +
PGI and/or PGI/PGII
low
G-17b usually elevated
PGI and/or PGI/PGII
normal
G-17b low
PGI and/or PGI/PGII
low
G-17b low
Atrophic pan-
gastritis
Atrophic gastritis
(antrum)
or
Increased secretion
of gastric acid
Atrophic gastritis
(corpus)
or
Hypochlorhydric of
achlorhydric stomach
Increased risk of
gastric or duodenal
ulcer
No risk of a stomach
disease
    Gastroscopy does
not produce
clinically significant
additional
information
     Other diseases,
such as intestinal
diseases, lactose
intolerance, celiac
disease, gall stones,
must be excluded
      Eradicate
H. pylori infection
     Consider
gastroscopy
Increased risk of gastric
cancer
Malabsorption (B12, iron,
calcium, magnesium,
some medicines)
Increased risk of gastric
cancer (atrophic gastritis)
Increased risk of gastric or
duodenal ulcer (increased
secretion of gastric acid)
Increased risk of
gastric cancer
Consider gastroscopy
Eradicate H. pylori infection
Figure 3. A guide and proposal for the application of a gastric biomarker panel in clinical practice and decision making. Abbreviations:
G-17b= plasmalevelof fasting amidatedgastrin-17;Atrophicpangastritis = AG thataffectsboth antrumand corpus(multifocal, advanced, and
extensive AG); PGI and PGII = plasma level of pepsinogen I and pepsinogen II, respectively.
Atrophic gastritis and biomarkers 143levels of gastrin-17 two- to ﬁvefold on average, the rise
being dependent on dose and usage of the drugs
[118]. The long-lasting use of PPIs and the conse-
quent rise of gastrin-17 will also result in a twofold rise
of plasma PGs due to hypertrophy of the oxyntic
glands, this hypertrophy, in turn, being likely a con-
sequence of trophic actions of the gastrin to the
corpus mucosa [118].
Atrophy of the antral mucosa (loss of antral G cells)
leads to a break in feedback control of the acid
secretion, i.e., in failure of the synthesis and release
of gastrin from the antral mucosa, and results in low
fasting and stimulated levels of amidated gastrin-17 in
the plasma [103].
In corpus-limited AG, the plasma fasting levels of
amidated gastrin-17 are always markedly increased
and are several tens of picomoles per liter (normally
2–5 pmol/l) [12,107]. In connection with low plasma
PGI and/or low PGI/PGII ratio, the high gastrin-17 in
plasma conﬁrms the AG limited in corpus and fundus
alone. If the gastrin-17 is not elevated, the AG occurs
in both antrum and corpus, i.e., the patient has an
extensive and multifocal AG (“panatrophy”;A Go f
OLGA stage III–IV).
In subjects without H. pylori infection or AG (the
biomarker panel is normal), the low plasma levels of
amidated gastrin-17 (<1–2 pmol/l) are hints of the
high output of stomach acid and suggest a high
intragastric acidity [34].
In subjects under PPI therapy, low or normal fast-
ing plasma levels of amidated gastrin-17 are a sug-
gestion of antral atrophy. On the other hand, a high
plasma level of amidated gastrin-17 in PPI users could
be seen as an indicator of normal antral mucosa and
suggests that the PPI treatment has lowered the acid
output properly.
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